Skip to main content
Top
Published in: Breast Cancer Research 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion

Authors: Meiou Dai, Amal A. Al-Odaini, Nadège Fils-Aimé, Manuel A. Villatoro, Jimin Guo, Ani Arakelian, Shafaat A. Rabbani, Suhad Ali, Jean Jacques Lebrun

Published in: Breast Cancer Research | Issue 1/2017

Login to get access

Excerpt

Main text: After publication of this work [1] an error was noticed in Fig. 5c. Figure 5c shows representative images/fields of PTGS2 staining of mammary tumors derived from mice injected with parental SCP2 cells versus mice injected with p21/cyclinD1 depleted SCP2 cells. Tissue slides from the two groups of animals were stained with an anti-PTGS2 antibody. Results showed a decrease in PTGS2 staining in the cyclinD1/p21 depleted group compared to the parental group.
Literature
1.
go back to reference Dai M, et al. Cyclin D1 cooperates with p21 to regulate TGFbeta-mediated breast cancer cell migration and tumor local invasion. Breast Cancer Res. 2013;15(3):R49.CrossRefPubMedPubMedCentral Dai M, et al. Cyclin D1 cooperates with p21 to regulate TGFbeta-mediated breast cancer cell migration and tumor local invasion. Breast Cancer Res. 2013;15(3):R49.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion
Authors
Meiou Dai
Amal A. Al-Odaini
Nadège Fils-Aimé
Manuel A. Villatoro
Jimin Guo
Ani Arakelian
Shafaat A. Rabbani
Suhad Ali
Jean Jacques Lebrun
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2017
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-017-0831-8

Other articles of this Issue 1/2017

Breast Cancer Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine